Zevra Therapeutics, Inc. (ZVRA) — 10-Q Filings
All 10-Q filings from Zevra Therapeutics, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 6, 2026
-
Zevra Swings to Profit on PRV Sale, Revenue Jumps
— Nov 5, 2025 Risk: medium
ZEVRA THERAPEUTICS, INC. reported a significant increase in revenue, net, to $26.063 million for the three months ended September 30, 2025, up from $3.695 milli -
Zevra's Q2 Losses Widen Amidst R&D Spend
— Aug 12, 2025 Risk: high
ZEVRA THERAPEUTICS, INC. reported a net loss of $17.3 million for the three months ended June 30, 2025, a significant increase from the $12.1 million net loss i -
Zevra Therapeutics Q1 2025: Minimal Revenue, Significant Net Loss
— May 13, 2025 Risk: high
Zevra Therapeutics, Inc. reported its first quarter 2025 results ending March 31, 2025. The company had minimal revenue of $1,528 for the quarter, a decrease fr -
Zevra Therapeutics Q3 2024 Update
— Nov 13, 2024 Risk: medium
Zevra Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $54.8 million and total liabilities of $4 -
Zevra Therapeutics Q2 2024: Net Loss Widens
— Aug 14, 2024 Risk: high
Zevra Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2024. The company had total assets of $43.11 million and total liabilitie -
Zevra Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: low
ZEVRA THERAPEUTICS, INC. (ZVRA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Zevra Therapeutics, Inc. reported financial results for the quarter
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX